MiR-98 has been linked to several key pathways in HCC, notably inhibiting the Wnt/β-catenin signaling pathway, targeting genes such as EZH2 and IGF2BP1, and impacting drug resistance mechanisms. The gene discussed is IGF2BP1; the disease is hepatocellular carcinoma.